Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Opko Health (OPK) stock in plain English

Free brief · no signupStart here
OPKPublished Nov 16, 2026
Opko Health Inc
Healthcare · Diagnostics & Research
Provides routine and esoteric laboratory diagnostic testing to healthcare providers across the United States.
Assets:
BioReference HealthClinical lab testing network operating nationwide
Rayaldee treatmentPrescription medicine for chronic kidney disease patients
4Kscore testProprietary blood test for prostate cancer risk assessment
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

51
OPS ScoreOperating finances
Latest quote
-4.73%$1.61
$1.20B
n/a (loss)
$502.29M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 16, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was OPK. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Opko Health (OPK) do?

Opko Health Inc (OPK) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Provides routine and esoteric laboratory diagnostic testing to healthcare providers across the United States. Combines a nationwide clinical testing laboratory business with proprietary prescription drug development and licensing. It is worth $1.20B on the market and sold $502.29M over the last year.

Market cap
$1.20B
P/E ratio
None (reported a loss)
Annual sales
$502.29M
Sector
Healthcare
Industry
Diagnostics & Research
Brief updated
Nov 16, 2026

Brands and businesses behind OPK

  • BioReference Health: Operates clinical laboratories providing diagnostic testing services to doctors and hospitals for direct fee revenue.
  • Rayaldee: Prescription medicine that generates sales revenue treating secondary hyperparathyroidism in chronic kidney disease patients.
  • 4Kscore: Proprietary blood test generating diagnostic fee revenue by assessing risk for aggressive prostate cancer.
  • GenPath: Specialized oncology testing unit earning revenue through advanced cancer and hereditary genetics screening.

OPK’s flags, in plain English

Each flag is a number from Opko Health’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 16, 2026.

Stupid Cash

Can pay this year's bills 5 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Insiders Hold

Insiders own 48.6% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Low debt

Low debt, only 46% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Burning Cash

Losing money, profit margin of -29.5%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more risk notes open with the free trial. Try it free for 7 days.

Questions about OPK

How big is Opko Health?

Opko Health’s market cap is $1.20B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $502.29M: what customers paid the company over the last year, before any costs.

What is OPK’s P/E ratio?

OPK has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with OPK?

The clinical laboratory business faces ongoing pressure from declining reimbursement rates by private insurers and Medicare. That is one risk on Opko Health’s card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Opko Health’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. OPK’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card